BPG is committed to discovery and dissemination of knowledge
Observational Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Cardiol. Apr 26, 2026; 18(4): 117928
Published online Apr 26, 2026. doi: 10.4330/wjc.v18.i4.117928
Demographic and clinical profile of patients with heart failure at a tertiary care hospital
Lotos Gailson, Abhishek Singh, Akshyaya Pradhan, Sudesh Prajapathi, Rajeev Choudhary, Monika Bhandari, Pravesh Vishwakarma, Ayush Shukla, Akhil Sharma, Gaurav Chaudhary, Sharad Chandra, Rishi Sethi, Sudhanshu Kumar Dwivedi
Lotos Gailson, Abhishek Singh, Akshyaya Pradhan, Rajeev Choudhary, Monika Bhandari, Pravesh Vishwakarma, Ayush Shukla, Akhil Sharma, Gaurav Chaudhary, Sharad Chandra, Rishi Sethi, Sudhanshu Kumar Dwivedi, Department of Cardiology, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India
Sudesh Prajapathi, Department of Cardiology, All India Institute of Medical Sciences, Bhopal 462026, Madhya Pradesh, India
Co-first authors: Lotos Gailson and Abhishek Singh.
Author contributions: Gailson L and Singh A equally contributed to this manuscript and are co-first authors. Gailson L and Pradhan A conceived the project; Gailson L, Singh A and Pradhan A were involved in data collection; Bhandari M, Vishwakarma P and Gailson L were instrumental in data organization and collation; Gailson L, Shukla A and Pradhan A performed the statistical analysis; Sharma A, Pradhan A and Chaudhary G performed literature search; Gailson L, Chandra S and Prajapathi S prepared the first draft; Chandra S and Sethi R critically reviewed the manuscript; Dwivedi SK, Sethi R and Pradhan A approved the final version; Pradhan A performed the journal search and submitted the initial version to journal.
Institutional review board statement: Ethical clearance was obtained from the Institutional Ethics Committee of King George’s Medical University prior to the commencement of the study, No. 83/Ethics/2020.
Informed consent statement: All participants provided informed written consent in English or Hindi, as per their preference.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Data is available with the corresponding author and can be shared on request.
Corresponding author: Akshyaya Pradhan, MD, DM, Professor, Department of Cardiology, King George’s Medical University, Shahmina Road, Chowk, Lucknow 226003, Uttar Pradesh, India. akshyaya33@gmail.com
Received: December 18, 2025
Revised: January 14, 2026
Accepted: March 9, 2026
Published online: April 26, 2026
Processing time: 116 Days and 10.6 Hours
Abstract
BACKGROUND

Heart failure (HF) is prevalent worldwide; however, due to the absence of a dedicated monitoring system in India, an adequate assessment of epidemiological trends in HF remains unaccomplished. Determining the profile of patients with HF facilitates early detection and therapy, minimising the disease burden.

AIM

To describe the demographics, clinical characteristics, haematological and biochemical parameters, electrocardiogram and echocardiogram findings and recognise the various causes of HF in India.

METHODS

This was an observational study conducted between May 2019 and December 2020 at a tertiary-care institution in North India. Consecutive adult patients with clinically stable chronic HF were enrolled. Demographic characteristics, clinical features, laboratory parameters, electrocardiographic findings, echocardiographic data, and HF etiology were recorded using a standardised questionnaire.

RESULTS

This study enrolled a total of 407 chronic HF patients with a mean age of 58.8 years, 64.4% of whom were male. The mean left ventricular ejection fraction was 38.47%. Ischemic heart disease is the leading cause of HF, accounting for 53.6% of the population. Diabetes was the most prevalent linked co-morbidity (28.6%), followed by hypertension (21.5%). The majority of individuals had HF with reduced ejection fraction (58.5%), and the most frequent presenting symptom was exertional dyspnea. Complete guideline-directed medical therapy, defined as concurrent use of an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta blocker, and mineralocorticoid receptor antagonist (in any dose), was achieved in 64% of patients. Newer therapies like angiotensin receptor-neprilysin inhibitors were prescribed in only 6.6% of patients. Of 95.6% patients were in sinus rhythm (atrial fibrillation in 4.4%). The other findings included left bundle branch block (21.1%), left anterior hemiblock with right bundle branch block (10.2%), and right bundle branch block (7.6%).

CONCLUSION

HF in this cohort occurred at a younger age and was predominantly ischemic in etiology, with most patients having HF with reduced ejection fraction. Despite reasonable guideline-directed medical therapy prescription rates, suboptimal dosing and low uptake of newer therapies highlight the need for structured HF care and improved access to evidence-based treatment in India.

Keywords: Coronary artery disease; Echocardiogram; Ejection fraction; Electrocardiogram; Heart failure; Ischemic heart disease; N-terminal pro-B-type natriuretic peptide; Trivandrum heart failure registry

Core Tip: Heart failure (HF) in India represents a growing public health challenge, affecting patients at a younger age and predominantly driven by ischemic heart disease. In this hospital-based study from North India, most patients had HF with reduced ejection fraction and a high burden of diabetes and hypertension. Although prescription rates of guideline-directed medical therapy were relatively high, only 64% of patients received all three foundational HF drugs, and uptake of newer therapies such as angiotensin receptor-neprilysin inhibitors was low. These findings highlight critical gaps in surveillance, early risk factor control, and optimisation of evidence-based HF care in India.